Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Non-Current Assets (2018 - 2025)

Historic Other Non-Current Assets for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $16.9 million.

  • Revolution Medicines' Other Non-Current Assets rose 6400.0% to $16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year increase of 6400.0%. This contributed to the annual value of $12.1 million for FY2024, which is 7246.87% up from last year.
  • Revolution Medicines' Other Non-Current Assets amounted to $16.9 million in Q3 2025, which was up 6400.0% from $31.4 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Other Non-Current Assets ranged from a high of $31.4 million in Q2 2025 and a low of $1.1 million during Q1 2021
  • For the 5-year period, Revolution Medicines' Other Non-Current Assets averaged around $7.0 million, with its median value being $2.9 million (2022).
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 55354.06% in 2023, then tumbled by 948.73% in 2024.
  • Quarter analysis of 5 years shows Revolution Medicines' Other Non-Current Assets stood at $1.7 million in 2021, then skyrocketed by 64.48% to $2.9 million in 2022, then surged by 146.13% to $7.0 million in 2023, then surged by 72.47% to $12.1 million in 2024, then surged by 38.94% to $16.9 million in 2025.
  • Its last three reported values are $16.9 million in Q3 2025, $31.4 million for Q2 2025, and $13.1 million during Q1 2025.